Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force

Botulinum toxin (BT) therapy is an established treatment of spasticity due to stroke. For multiple sclerosis (MS) spasticity this is not the case. IAB-Interdisciplinary Working Group for Movement Disorders formed a task force to explore the use of BT therapy for treatment of MS spasticity. A formali...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of neurology Vol. 264; no. 1; pp. 112 - 120
Main Authors:	Dressler, Dirk, Bhidayasiri, Roongroj, Bohlega, Saeed, Chahidi, Abderrahmane, Chung, Tae Mo, Ebke, Markus, Jacinto, L. Jorge, Kaji, Ryuji, Koçer, Serdar, Kanovsky, Petr, Micheli, Federico, Orlova, Olga, Paus, Sebastian, Pirtosek, Zvezdan, Relja, Maja, Rosales, Raymond L., Sagástegui-Rodríguez, José Alberto, Schoenle, Paul W., Shahidi, Gholam Ali, Timerbaeva, Sofia, Walter, Uwe, Saberi, Fereshte Adib
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 2017 Springer Nature B.V
Subjects:	Acetylcholine Release Inhibitors - therapeutic use Botulinum toxin Botulinum Toxins - therapeutic use Hospitals Humans Interdisciplinary aspects Medicine Medicine & Public Health Movement disorders Multiple sclerosis Multiple Sclerosis - classification Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Multiple Sclerosis - physiopathology Muscle Spasticity - classification Muscle Spasticity - drug therapy Muscle Spasticity - etiology Muscle Spasticity - physiopathology Neurology Neuroradiology Neurosciences Observational studies Original Communication Spasticity Stroke Task forces Working groups Iran Germany Russia Recommendations Multiple sclerosis Spasticity IAB-Interdisciplinary Working Group for Movement Disorders Review Botulinum toxin Therapeutic use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Botulinum toxin (BT) therapy is an established treatment of spasticity due to stroke. For multiple sclerosis (MS) spasticity this is not the case. IAB-Interdisciplinary Working Group for Movement Disorders formed a task force to explore the use of BT therapy for treatment of MS spasticity. A formalised PubMed literature search produced 55 publications (3 randomised controlled trials, 3 interventional studies, 11 observational studies, 2 case studies, 35 reviews, 1 guideline) all unanimously favouring the use of BT therapy for MS spasticity. There is no reason to believe that BT should be less effective and safe in MS spasticity than it is in stroke spasticity. Recommendations include an update of the current prevalence of MS spasticity and its clinical features according to classifications used in movement disorders. Immunological data on MS patients already treated should be analysed with respect to frequencies of MS relapses and BT antibody formation. Registration authorities should expand registration of BT therapy for spasticity regardless of its aetiology. MS specialists should consider BT therapy for symptomatic treatment of spasticity.
Bibliography:	SourceType-Scholarly Journals-1 ObjectType-Instructional Material/Guideline-1 ObjectType-Feature-4 content type line 23 ObjectType-Review-2 ObjectType-Article-3 ObjectType-Article-1 ObjectType-Feature-2
ISSN:	0340-5354 1432-1459
DOI:	10.1007/s00415-016-8304-z